In his correspondence, Jones raises questions regarding study methodology, potential confounding factors related to LDL cholesterol response observed in different populations treated with the same dose of atorvastatin therapy, alternative explanations for differences in short- and long-term treatment to goal rates in head-to-head comparisons of simvastatin and atorvastatin, doubt about development of LDL cholesterol tachyphylaxis with any HMG CoA reductase inhibitor (statin) over the time course observed in our study, and the uniqueness of tachyphylaxis to a particular agent based on half-life.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jones P.
        • Kafonek S.
        • Laurona I.
        • Humminghake D.
        Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
        Am J Cardiol. 1998; 81: 582-587
        • Pitt B.
        • Waters D.
        • Brown W.V.
        • van Boven A.J.
        • Schwartz L.
        • Title L.M.
        • Eisenberg D.
        • Shurzinske L.
        • McCormick L.S.
        Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
        N Engl J Med. 1999; 341: 70-76
        • Nawrocki J.W.
        • Weiss S.R.
        • Davidson M.H.
        • Sprecher D.L.
        • Schwartz S.L.
        • Lupien P.J.
        • Jones P.H.
        • Haber H.E.
        • Black D.M.
        Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
        Arterioscler Thromb Vasc Biol. 1995; 15: 678-682
        • Stern R.H.
        • Yang B.B.
        • Hounslow N.J.
        • MacMahon M.
        • Abel R.B.
        • Olson S.C.
        Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
        J Clin Pharmacol. 2000; 40: 616-623
      1. Schwartz GG, Olsson AG, Ezekowitz MP, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman B, Leslie S, Stern T, for the MIRACL Investigators. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial: effects of intensive atorvastatin treatment on early recurrent events after an acute coronary syndrome. American Heart Association Scientific Sessions, November 2000, New Orleans, LA.

        • Sueta C.A.
        • Showdhury M.
        • Boccuzzi S.J.
        • Smith Jr, S.C.
        • Alexander C.M.
        • Londhe A.
        • Lulla A.
        • Simpson Jr, R.J.
        Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease.
        Am J Cardiol. 1990; 83: 1303-1307
        • Brown A.S.
        • Bakker-Arkema R.G.
        • Yellen L.
        • Henley Jr, R.W.
        • Guthrie R.
        • Campbell C.F.
        • Koren M.
        • Woo W.
        • McLain R.
        • Black D.M.
        Treating patients with documented atherosclerosis to National Cholesterol Education Program–recommended low-density lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
        J Am Coll Cardiol. 1998; 32: 665-672
        • Dart A.
        • Jerums G.
        • Nicholson G.
        • d’Emden M.
        • Hamilton-Craig I.
        • Tallis G.
        • Best J.
        • West M.
        • Sullivan D.
        • Bracs P.
        • Black D.
        A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
        Am J Cardiol. 1997; 80: 39-44
        • Heinonen T.M.
        • Stein E.
        • Weiss S.R.
        • McKenney J.M.
        • Davidson M.
        • Shurzinske L.
        • Black D.M.
        The lipid-lowering effects of atorvastatin, a new HMG CoA reductase inhibitor.
        Clin Ther. 1996; 18: 853-863
        • Conde K.
        • Roy S.
        • Freake H.C.
        • Newton R.S.
        • Fernandez M.L.
        Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
        Lipids. 1999; 34: 1327-1332
        • Bisgaier C.L.
        • Essenburg A.D.
        • Auerbauch B.J.
        • Pape M.E.
        • Sekerke C.S.
        • Gee A.
        • Woole S.
        • Newton R.S.
        Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
        J Lipid Res. 1997; 38: 2502-2515

      Linked Article